Breast Cancer Clinical Trial
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Summary
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.
The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.
Eligibility Criteria
Inclusion Criteria:
Is 18 Years and older in the United States or 20 Years and older in Japan
Has a pathologically documented advanced/unresectable or metastatic breast cancer
Documented HER3-positive disease measured by immunohistochemistry (IHC)
Has disease that is refractory to or intolerable with standard treatment, or for which standard treatment no longer is available
Has an Eastern Cooperative Oncology Group Performance Status 0-1
Has Left Ventricular Ejection Fraction ≥ 50%
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the neoadjuvant, adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part Only:
Is able to submit a fresh tumor biopsy sample prior to starting study treatment if not already submitted for HER3 expression
Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:
Has documented hormone (estrogen and progesterone) receptor (HR)-negative and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines
Has progressed after receiving 1 to 2 prior chemotherapy regimens for advanced/unresectable or metastatic breast cancer.
Exclusion Criteria:
Prior treatment with a HER3 antibody
Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)
Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment
Has a medical history of myocardial infarction or unstable angina
Has a corrected QT prolongation to > 450 millisecond (ms) in males and > 470 ms in females
Has a medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period
Has clinically significant corneal disease
Additional Exclusion Criteria for Dose Expansion Part:
Prior treatment with an govitecan derivative (eg, IMMU-132).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 26 Locations for this study
Newnan Georgia, 30265, United States
Chicago Illinois, 60611, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02215, United States
Bronx New York, 10467, United States
New York New York, 10022, United States
Dallas Texas, 75231, United States
Dallas Texas, 75390, United States
Houston Texas, 77030, United States
San Antonio Texas, 78229, United States
Sapporo-Shi Hokkaido, 003-0, Japan
Chiba , 277-8, Japan
Fukushima , 960-1, Japan
Hiroshima , 730-5, Japan
Kagoshima , 892-0, Japan
Kanagawa , 241-0, Japan
Kumamoto , 860-8, Japan
Nagoya , 464-8, Japan
Nagoya , 467-8, Japan
Osaka , 540-0, Japan
Osaka , 541-8, Japan
Osaka , 589-8, Japan
Saitama , 350-1, Japan
Saitama , 362 0, Japan
Tokyo , 104-0, Japan
Tokyo , 135-8, Japan
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.